178876-84-1

Basic information

• Product Name: 6-Acetylamino-5-bromo-pyridine-2-carboxylic acid methyl ester
• CAS NO: 178876-84-1
• Molecular Weight: 273.086
• Mol File: 178876-84-1.mol
• Article Data: 5

Chemical Properties

• Boiling Point: 462.3±45.0 °C(Predicted)
• Density: 1.608±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 6-Acetylamino-5-bromo-pyridine-2-carboxylic acid methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Acetylamino-5-bromo-pyridine-2-carboxylic acid methyl ester(178876-84-1)
• EPA Substance Registry System: 6-Acetylamino-5-bromo-pyridine-2-carboxylic acid methyl ester(178876-84-1)

Safety Data

• Hazardous Substances Data: 178876-84-1(Hazardous Substances Data)

Upstream product

• 26893-72-1 6-acetamido-picolinic acid 
• 36052-26-3 methyl 6-aminopyridine-2-carboxylate 
• 5327-33-3 2-acetylamino-6-methylpyridine 
• 1824-81-3 2-Amino-6-methylpyridine 
• 108-24-7 acetic anhydride 
• 178876-82-9 6-amino-5-bromo-pyridine-2-carboxylic acid methyl ester 

Relevant articles and documents

PYRROLIDINE AND BICYCLOHETEROARYL CONTAINING OGA INHIBITOR COMPOUNDS

The present invention relates to O-GIcNAc hydrolase (OGA) inhibitors. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations; or alpha synucleinopathies, in particular Parkinson's disease, dementia due to Parkinson's (or neurocognitive disorder due to Parkinson's disease), dementia with Lewy bodies, multiple system atrophy, or alpha synucleinopathy caused by Gaucher's disease.

OGA INHIBITOR COMPOUNDS

The present invention relates to O-GIcNAc hydrolase (OGA) inhibitors having the structure shown in formula (I). The invention is also directed to pharmaceutical compositions comprising such compounds to processes for preparing such compounds and compositions, and to the use of such compounds and compositions for the prevention and treatment of disorders in which inhibition of OGA is beneficial, such as tauopathies, in particular Alzheimer's disease or progressive supranuclear palsy; and neurodegenerative diseases accompanied by a tau pathology, in particular amyotrophic lateral sclerosis or frontotemporal lobe dementia caused by C90RF72 mutations. wherein RB is an aromatic heterobicyclic radical selected from the group consisting of (b-1) to (b-6).

Total synthesis of dimethyl sulfomycinamate

Dimethyl sulfomycinamate (1), a methanolysis product from the natural antibiotic sulfomycin I, is synthesized in 11 steps. The chemistry of various pyridine, thiazole, and oxazole heterocycles and their coupling reactions under palladium catalysis are examined. The key transformations in the synthesis are the selective palladium-catalyzed coupling reactions on doubly activated pyridine 62 and the condensation reaction between bromo ketone 69 and amide 28 to form the oxazole moiety 76. The first preparation of oxazole triflates is described, as are some of their chemical properties.